Antithymocyte globulins (ATGs), the immunoglobulin G (IgG) division of sera starting rabbits or horses immunized with human thymocytes or T-cell lines, are used in conditioning regimens for bone marrow transplantation, in the treatment of acute graft-versus-host virus. In non human primates, ATGs induce rapid, dose-dependent, T-cell depletion in marginal lymphoid tissues, where apoptotic cells can be demonstrated in T-cell zones.

Anti thymocyte globulin (ATG) is an valuable treatment in patients with strict a plastic anemia (SAA). Its mechanism of action remains uncertain, although it has been implicit to be immunosuppressive. Still, ATG has also been shown by several laboratories to be immunostimulatory. newly, interleukin-1 (IL-1) production has been found to be decreased in lipopolysaccharide-stimulated peripheral blood monocytes obtain from SAA patients.

Antithymocyte globulins (ATG) are effective therapies in aplastic anemia; their mechanism of action is undefined. We assayed multiple properties of ATG to address the biological and immunological bases for differences between ATG and lot difference. In adding together, we studied a lot reported to be inactive in an American clinical trial; still in retrospect, this lot appeared to be active in patients treated in Europe. Immunoprecipitation of thymocytes and lymphocyte membrane proteins with ATG show relating 14 and 18 major bands on SDS-PAGE, except the patterns for ATG were not equal.